Literature DB >> 35896759

The Effect of Goal-Directed Fluid Administration on Outcomes After Pancreatic Surgery.

Julie B Siegel1, Ryan O'Leary2, Bryce DeChamplain2, William P Lancaster2.   

Abstract

BACKGROUND: We evaluated the effect of an Enhanced Recovery After Surgery protocol on intraoperative fluid administration and postoperative outcomes in pancreatic surgery.
METHODS: Pancreatic cancer resections at our institution from 2012 to 2018 were grouped according to pre- or post-protocol initiation. Preoperative characteristics and postoperative outcomes were compared with Fisher's exact test and chi-square for categorical variables, and Mann-Whitney U test for continuous variables. Further analysis separated patients that had a Whipple from those who had distal pancreatectomy.
RESULTS: A total of 263 patients underwent pancreatic cancer resection during the study period (169 Whipples, 84 DPs, 92 pre-ERAS and 171 post-ERAS). Intraoperative fluid administration significantly decreased after protocol implementation (mean 6,277 ml vs. 3870 ml, p < 0.001). This held true when separating patients that had a Whipple procedure from those that had a DP (6,929 ml vs. 4,513 ml, p < 0.001, 5,060 ml vs. 2,833 cc, p = 0.002, respectively). Intensive care unit (ICU) admission (41.3% vs. 20.5%, p < 0.001) and length of stay (9.4 vs. 8.1 days, p < 0.01) were significantly reduced after ERAS implementation for all patients and in Whipple patients alone (47.5% vs. 23.6%, p = 0.002 and 10.7 vs. 6.6 days, p = 0.004). DP patients also had significantly decreased ICU admissions (41.3% vs. 20.5%, p = 0.045). All other postoperative outcomes were not significantly different.
CONCLUSION: For patients undergoing pancreatic cancer resection, goal-directed fluid management is associated with decreased intraoperative fluid administration, decreased ICU admission, and decreased length of stay without an increase in postoperative complications or readmission.
© 2022. The Author(s) under exclusive licence to Société Internationale de Chirurgie.

Entities:  

Mesh:

Year:  2022        PMID: 35896759     DOI: 10.1007/s00268-022-06676-w

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  6 in total

Review 1.  Systematic review and meta-analysis of enhanced recovery after pancreatic surgery with particular emphasis on pancreaticoduodenectomies.

Authors:  M M E Coolsen; R M van Dam; A A van der Wilt; K Slim; K Lassen; C H C Dejong
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

2.  Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy.

Authors:  Marco Braga; Nicolò Pecorelli; Riccardo Ariotti; Giovanni Capretti; Massimiliano Greco; Gianpaolo Balzano; Renato Castoldi; Luigi Beretta
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

3.  Postoperative morbidity following pancreatic cancer surgery is significantly associated with worse overall patient survival; systematic review and meta-analysis.

Authors:  Ioannis Mintziras; Sabine Wächter; Jerena Manoharan; Veit Kanngiesser; Elisabeth Maurer; Detlef Klaus Bartsch
Journal:  Surg Oncol       Date:  2021-04-06       Impact factor: 3.279

Review 4.  Intraoperative fluid management: Past and future, where is the evidence?

Authors:  Abdulmohsin A Al-Ghamdi
Journal:  Saudi J Anaesth       Date:  2018 Apr-Jun

Review 5.  Goal-directed fluid therapy in the perioperative setting.

Authors:  Julia B Kendrick; Alan David Kaye; Yiru Tong; Kumar Belani; Richard D Urman; Christopher Hoffman; Henry Liu
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019-04

6.  Restrictive intraoperative fluid optimisation algorithm improves outcomes in patients undergoing pancreaticoduodenectomy: A prospective multicentre randomized controlled trial.

Authors:  Laurence Weinberg; Damian Ianno; Leonid Churilov; Ian Chao; Nick Scurrah; Clive Rachbuch; Jonathan Banting; Vijaragavan Muralidharan; David Story; Rinaldo Bellomo; Chris Christophi; Mehrdad Nikfarjam
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.